Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.16 +0.61 (+3.69%)
Official Closing Price Updated: 6:30 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Wall Street Waits With Bated Breath For Nvidia Earnings After Tech Selloff, Fed Minutes Eyed: Analyst Flags This As Biggest Risk For Market ↗
The market will broaden the sustenance of its rally when interest-rate cuts begin to be priced in and investors begin to think about the roadmap, an analyst said. 
Via Benzinga
Topics Economy
News headline image
Earnings Scheduled For February 21, 2024 ↗
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
News headline image
Bausch & Lomb Earnings Preview ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Bausch & Lomb ↗
 
Via Benzinga
News headline image
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month ↗
"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins... 
Via Benzinga
News headline image
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch & Lomb Earnings Preview ↗
 
Via Benzinga
News headline image
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
News headline image
6 Analysts Have This to Say About Bausch & Lomb ↗
 
Via Benzinga
News headline image
Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News' ↗
U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings. 
Via Benzinga
Topics Economy Stocks
News headline image
Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting
From Bausch + Lomb
Via Business Wire
News headline image
Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift ↗
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy... 
Via Benzinga
News headline image
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
Via ACCESSWIRE
News headline image
Bausch + Lomb Completes Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Pricing of Senior Secured Notes Offering
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
Via ACCESSWIRE
News headline image
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.